Christopher Geven completed his MSc in Medicine in 2013. In the year thereafter, he worked as a resident physician at the department of Intensive Care of the Radboudumc. Since December 2014, he is a PhD-candidate at the department of Intensive Care Medicine. The main focus of his research is a potential new sepsis drug named Adrecizumab. His research involves experimental studies in both animals and humans as well as clinical trials.
Our main aim is to achieve a greater understanding of the molecular mechanisms of disease. By integrating fundamental and clinical research, we obtain multifaceted knowledge of (patho)physiological processes.